It is noteworthy that the combination of MCL1 inhibitors with AZA is currently in clinical trials for hematological cancers, which will likely provide useful information and help in moving this combination to clinical trials for melanoma patients quickly. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.